44th Annual Report of Phaarmasia Limited for the financial year 2024-25, along with the notice of the Annual General Meeting.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Phaarmasia Ltd has submitted its 44th Annual Report for FY 2024-25 along with the AGM notice to BSE. The 44th AGM is scheduled for Thursday, 25th September 2025 at 4:00 PM via video conferencing. Key business to be transacted includes adoption of audited financials, reappointment of Mr. Naga Bhaskara Rao Yallapragada as Whole-time Director (by rotation), appointment of Mr. NVSS Suryanarayana Rao as Secretarial Auditor for a 5-year term (FY 2024-25 to 2028-29), approval for related party transactions up to Rs. 100 Crores for FY 2025-26 (with parent companies Maneesh Pharmaceuticals and Svizera Health, and Shub Pharma Agency), and an increase in the Whole-time Director's CTC to Rs. 35 Lakhs per annum. The company's revenue from operations declined to Rs. 24.37 Crores from Rs. 30.59 Crores in the previous year, while net loss widened significantly to Rs. 158.94 Lakhs from Rs. 51.82 Lakhs in FY 2023-24.
The widening net loss (roughly 3x deeper) and ~20% revenue decline point to weakening operational performance that shareholders should note. The proposed Rs. 100 Crore related party transaction limit is substantial relative to the company's revenue base, warranting close review by shareholders before voting at the AGM on 25th September.